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Abstract
Background: High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is
the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA.
However, the risk/benefit profile has been questioned limiting its world-wide use. In the late
nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to
verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without
increasing the toxicity profile. The safety analysis in the first 169 patients who completed the
treatment is here described.
Methods:  Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d
intravenously (IV) 5 days/week × 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25
to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week × 4
weeks followed by 10 MU/m2 subcutaneously (SC) three times per week × 48 weeks (High Dose
Interferon, HDI, arm). Toxicity was recorded and graded, according to the WHO criteria, as the
worst grade that occurred during each cycle.
Results: The most common toxicities in both arms were flu-like and gastrointestinal symptoms,
leukopenia, liver and neuro-psichiatric morbidities; with regard to severe toxicity, only leukopenia
was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this
did not cause an increase in the infection risk. Discontinuation of treatment, due to toxicity, was
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observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively. The median actual
dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that
delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003).
Conclusion: Four cycles of intravenous high-dose IFNalfa-2b can be safely delivered with an
increase in the median dose intensity. Efficacy results from this trial are eagerly awaited.
Background
Melanoma is the most aggressive skin cancer and poses an
increasingly important health problem. Surgery offers the
best chance for cure in the early stage of disease. However,
when melanoma is detected with a thickness of > 4.0 mm
or in the presence of regional lymph node involvement,
the risk of recurrence and death becomes higher. The 5-
year overall survival, in node positive patients, ranges
from 26 to 69%, depending on the number of lymph
nodes involved, whether they were identified microscopi-
cally or clinically, or whether the primary melanoma was
ulcerated or not [1,2].
Moreover, chemotherapy and immunotherapy have a
limited efficacy when the disease becomes metastatic, and
in those patients the median survival time is estimated to
be 8.1 months (95% confidence interval: 7.3–8.9), with a
long-term survival over 5 years of 2.3% [3]. Therefore, it is
of paramount importance to find effective adjuvant ther-
apies for melanoma patients at high risk of recurrence.
Interferon-α2b (IFNα2b) has proved to have some con-
sistent anti tumor activity in locally advanced [4] and met-
astatic disease and has been tested in clinical trials, in the
adjuvant setting, in a variety of dosage regimens. So far, in
patients with node involvement and/or a Breslow's thick-
ness > 4 mm (stage IIB and III), only 1-year of high dose
IFNα2b (HDI) has been shown to significantly reduce the
risk of relapse and death compared with observation [5]
and with a ganglioside vaccine [6]. However, this regimen
is associated with significant toxicity and, despite its
approval by the US Food and Drug Administration and by
the European Medicines Agency, its widespread accept-
ance has been limited: it is estimated that less than 20%
of the Italian node-positive melanoma patients receive
adjuvant IFNα2b treatment. Concerns about its tolerance
increased after the publication of the E1690/S9111/
C9190 inter-group study which confirmed the benefits on
disease-free survival, as seen in the ECOG 1684 study, but
failed to show any survival benefit, thus increasing the
skepticism about the efficacy of this treatment. The subse-
quent E1694/S9512/C509801 inter-group study showed
a significant increase in disease-free and overall survival of
patients treated with HDI compared with the GM2/KLH/
QS21 ganglioside vaccine. However, this finding did not
change the world-wide debate on whether the clinical
benefit (25% improvement in the relative overall sur-
vival) [7] could be offset by its toxicity. This issue has not
been resolved yet, despite the study of Cole et al [8]
showed a gain in the quality-of-life-adjusted survival time
in the treated group when compared to the observation
group.
The distinguishing feature of the ECOG 1684 regimen was
a 4 week, intravenous, high dose induction phase, fol-
lowed by 48 weeks of subcutaneous administration. The
analysis of the survival curves in the E1684 study points
out an early separation in the curves, thus suggesting that
the higher plasma concentrations, achieved with the intra-
venous induction phase, may be critical and necessary for
clinical benefit [5]. With the aim of further exploring this
aspect, and of reducing the duration of the treatment, the
Italian Melanoma Inter-group planned a spontaneous
randomized study to determine if the intensive intrave-
nous induction regimen repeated for 4 times could
improve relapse-free and overall survival compared with
the standard 1-year HDI regimen.
We chose to give four induction cycles in order to admin-
ister a similar amount of total interferon in the two treat-
ment arms, and simultaneously to reduce the time spent
by the patients on therapy. We decided to restrict the
accrual only to node-positive melanoma patients in order
to have a more homogeneous risk population. Acknowl-
edging that the toxicity of HDI is a substantial issue, we
planned to carry out an interim safety analysis once at
least 50% of all patients had completed their treatment.
We hereby report the results of this safety analysis in the
first 169 patients treated.
Methods
Patient selection
Eligible patients had a histologically-proven stage III pri-
mary or recurrent melanoma of cutaneous origin, or clin-
ically detected nodal metastasis arising from an unknown
primary, without evidence of systemic disease (N1a, N1b,
N2a, N2b, N3, according to the revised AJCC stage group-
ings for melanoma [9]). Patients with satellite or in-transit
metastases and patients with extra capsular nodal involve-
ment or recurrence after a previous lymph node dissec-
tion, were excluded from the study. Patients had to
undergo radical excision of primary tumor with at least 2
cm margins and be submitted to therapeutic lym-
phadenectomy within 60 days before randomization.BMC Cancer 2006, 6:44 http://www.biomedcentral.com/1471-2407/6/44
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Patients with more than one lymphatic basin drainage
involved could be randomized providing all the lym-
phatic basins had been radically resected.
The definition of nodal metastasis required the identifica-
tion of tumor cells by routine stains, and neither immu-
nohistochemical stains nor positive reverse transcriptase
polymerase chain reactions alone were considered suffi-
cient for study entry.
Patients were required to meet the following criteria: an
age of 18 years or older, ECOG performance status of 0–
1, adequate organ function (bilirubin, SGOT, serum creat-
inine, and BUN within normal ranges) and no significant
medical or psychiatric or autoimmune co-morbidity.
Exclusion criteria were an age of more than 70 years, preg-
nancy, or lactation, and previous adjuvant therapy.
Randomization was carried out by telephone through the
Clinical Trials and Biostatistics Unit, the study data center
responsible for data management. A system of random
permuted blocks within the participating center strata was
used. Data were collected on paper case report forms and
recorded on an electronic database designed specifically
for the management of the trial.
All patients gave their written informed consent to receive
the treatment. The study was approved by the Ethics Com-
mittee of each participating center, in compliance with the
Helsinki Declaration.
Treatment
All patients were randomly assigned to the two treatment
groups: IFNα2b 20 MU/m2 /d IV 5 days/week × 4 weeks,
repeated for three times on weeks 9 to 12, 17 to 20, 25 to
28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNα2b
20 MU/m2 /d IV 5 days/week × 4 weeks followed by 10
MU/m2 SC three times per week × 48 weeks (High Dose
Interferon, HDI, arm). The IV IFNα2b doses were admin-
istered in 20' diluted in 100 ml of saline, the subcutane-
ous doses were self-administered. We defined 4 weeks of
treatment as a cycle, in both arms, in order to evaluate the
dose intensity and the dose delivered. Patients received
oral paracetamol 1,000 mg 30' before IFNα2b administra-
tion, and subsequently, as needed, up to a maximum of
3,000 mg/d, to prevent and control IFN-related fever and
flu-like symptoms; ondansetron 8 mg or granisetron 3 mg
IV were used to prevent nausea and emesis, omeprazole
20 or 40 mg/d was used in case of gastric acidosis or in
patients with a history of gastric ulcer disease; multivita-
min intake and physical exercise were strongly recom-
mended to all patients, and iron supplement was added
when the hemoglobin decreased more than three mg
from the initial value. Patients were monitored for toxicity
and compliance, by physical examination, hematology
and serum chemistry profiles, weekly during the intrave-
nous administration of IFNα2b and monthly during the
subcutaneous administration, then, at the end of the treat-
ment, every 3 months for a period of 2 to 5 years, and after
the fifth year, every 6 months for disease progression.
The toxicity was recorded and graded, according to the
World Health Organization (WHO) criteria, as the worst
grade that occurred during each cycle. Treatment was
resumed with a 30% dose reduction in case of a grade 3/4
toxicity; after a second episode of grade 3/4 toxicity, a
60% dose reduction was required. In case of complete
recovery during the rest period, a dose re-escalation was
attempted at subsequent cycles, for patients randomized
to DD/DI arm. Dose re-escalation was not attempted oth-
erwise.
Statistical methods
The primary endpoint of the study was the 5-year overall
survival in the intent-to-treat population. Secondary end-
points were relapse-free survival, site of relapse, safety and
prospective evaluation of quality of life.
The sample size was determined by assuming a 55% 5-
year overall survival for patients treated in the HDI arm
and hypothesizing an increase of 15% in patients treated
in the DD/DI arm; a recruitment of at least 328 patients
was required to verify the hypothesis with an 80% power
and a 5% error (2-sided test). An interim analysis was
planned when at least 50% of the required patients had
completed the planned treatment, to verify whether or not
it was feasible to administer high doses of Interferon only
intravenously without significantly increasing the toxicity.
No formal criteria for study discontinuation were defined
but the decision to continue or discontinue was left up to
the protocol committee board.
Toxicity was analyzed in an "as treated" population, pro-
vided they had received at least one dose of therapy. To
assess toxicity and feasibility of the treatment, the two
arms were compared in terms of all grade distribution
using Wilcoxon' s rank sum test. Difference in occurrence
of Grade 3/4 toxicity events between arms was assessed
using Fishers exact test.
Actual Dose Intensity (ADI) of Interferon was calculated
as recommended by Hryniuk [10], the number of IFNα2b
MU being delivered per square meter per week for each
patient during the whole treatment. The median ADI was
compared using Wilcoxon' s rank sum test.
Adjustments for multiplicity were not made. All p values
were based on a two-sided testing, and statistical analysesBMC Cancer 2006, 6:44 http://www.biomedcentral.com/1471-2407/6/44
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were carried out with SAS statistical software (Release
8.02; SAS Institute, Cary, NC).
Results
Patient characteristics
From November '98 to July '05, 208 patients were
enrolled in the still ongoing study. This safety report con-
sidered only the first 169 patients enrolled until Decem-
ber 03, who had had enough time to complete the
treatment ("safety evaluable population"). Eighty-eight
patients were enrolled in the DD/DI arm and 81 in the
HDI arm. Three patients, two in DD/DI arm and one in
HDI arm respectively, did not start the treatment, one
because of lung metastases, whereas the other two with-
drew their consent immediately after the randomization.
Table 1 shows the demographic and baseline disease char-
acteristics of the patients. There were 101 males and 65
females, with a mean age of 49.1 years (SD 13.3). More
than 94% of patients had ECOG Performance Status equal
to 0. Ninety patients (54%) had the primary melanoma
located on the trunk, and in 40% of patients the
melanoma was ulcerated. The largest subgroup of patients
(61%) had one involved lymph node, 26% had two to
three involved lymph nodes, and 11% had four or more
involved lymph nodes. The main prognostic characteris-
tics were balanced between the treatment groups.
Toxicity evaluation
Adverse events per WHO grade of DD/DI arm vs. HDI arm
are reported in Table 2. Flu-like symptoms, (fatigue, fever
and arthro-myalgia), nausea/vomiting, anorexia, cytope-
nia, elevation of liver enzymes, and neuro-psychiatric
symptoms were the most frequently noted events in both
arms. The distribution of all grades of toxicity was similar
in the two groups, except for leukopenia, which was
higher in DD/DI arm (p = 0.016). We also observed a sta-
tistically significant higher frequency of hypotension in
HDI arm compared to DD/DI arm, however only grades 1
and 2 were observed.
Table 1: Patients' demographic and baseline disease characteristics
Number of patients (%)
Patients' characteristics DD/DI arm (N = 86) HDI arm (N = 80)
Age, years
Mean (SD) 47 (13) 52 (13)
Gender
Male 47 (55) 54 (67)
Female 39 (45) 26 (33)
ECOG Performance 
Status
0 81 (94) 76 (95)
1 5( 6 )4( 5 )
Site of primary tumor
Head/neck 3( 3 )6( 7 )
Trunk 50 (58) 40 (50)
Upper limb 7( 8 )6( 8 )
Lower limb 26 (30) 24 (30)
Unknown 0( 0 )4( 5 )
Ulceration
No 45 (52) 36 (45)
Yes 33 (39) 34 (43)
Unknown 8( 9 ) 1 0 ( 1 2 )
Breslow's thickness 
(mm)
≤ 1 2( 2 )7( 9 )
1.01 – 2.0 27 (31) 18 (23)
2.01 – 4.0 30 (35) 29 (36)
>4 22 (26) 17 (21)
Unknown 5( 6 )9 ( 1 1 )
Nodal classification
N0 0( 0 )2( 2 )
N1 56 (65) 46 (58)
N2 19 (22) 24 (30)
N3 11 (13) 8 (10)BMC Cancer 2006, 6:44 http://www.biomedcentral.com/1471-2407/6/44
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Table 2: Adverse events (all grades) by treatment arm
Number of patients (%)
DD/DI arm (N = 86) HDI arm (N = 80)
Event Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Flu-like symptoms
Fatigue 19 (22) 26 (30) 25 (29) 0 14 (17) 27 (34) 19 (24) 3 (4)
Fever 28 (33) 33 (38) 7 (8) 0 25 (31) 23 (29) 8 (10) 1 (1)
Rigors/chills 15 (17) 5 (6) 0 0 12 (15) 3 (4) 3 (4) 0
Arthralgia/myalgia 26 (30) 17 (20) 1 (1) 0 29 (36) 12 (15) 3 (4) 1 (1)
Sweating 8( 9 )3( 3 )0 0 8 ( 1 0 ) 1( 1 )1( 1 )0
Gastrointestinal
Nausea/vomiting 32 (37) 12 (14) 2 (2) 0 27 (34) 12 (15) 1 (1) 0
Constipation 13 (15) 5 (6) 0 0 9 (11) 3 (4) 0 0
Diarrhea 11 (13) 1 (1) 0 0 5 (6) 1 (1) 1 (1) 1 (1)
Anorexia 30 (35) 10 (12) 3 (3) 0 14 (17) 12 (15) 6 (7) 0
Hematological
Leukopenia 13 (15) 32 (37) 21 (24) 0 28 (35) 25 (31) 7 (9) 0
Anemia 12 (14) 0 1 (1) 0 16 (20) 3 (4) 0 0
Granulocytopenia 7 (8) 21 (24) 31 (36) 7 (8) 13 (16) 23 (29) 21 (26) 2 (2)
Platelets 1 1 ( 1 3 ) 1( 1 )3( 3 )1( 1 ) 1 6 ( 2 0 ) 5( 6 )0 0
Hemorrhage 2( 2 )4( 5 )0 0 1( 1 )1( 1 )0 0
Hepatic function
Bilirubin 3( 3 )2( 2 )0 0 6( 7 )0 0 0
SGOT/SGPT 16 (19) 11 (13) 18 (21) 15 (17) 21 (26) 24 (30) 18 (22) 3 (4)
Alkaline phosphatase 8( 9 )2( 2 )0 0 8 ( 1 0 ) 3( 4 )0 0
Liver dysfunction 0 2( 2 )1( 1 )0 3( 4 )1( 1 )1( 1 )0
Neurologic
Depression/anxiety 19 (22) 14 (16) 7 (8) 0 20 (25) 12 (15) 12 (15) 1 (1)
Cognitive disturbance 10 (12) 10 (12) 4 (5) 0 10 (12) 7 (9) 2 (2) 0
Cardiovascular
Hypertension 6( 7 )1( 1 )0 0 2( 2 )1( 1 )2( 2 )0
Hypotension 1( 1 )1( 1 )0 0 5( 6 )4( 5 )0 0
Ritmo 02 ( 2 ) 001 ( 1 ) 1 ( 1 ) 00
Cardiac dysfunction 6 (7) 4 (5) 0 0 7 (9) 6 (7) 2 (2) 1 (1)
Pulmonary
Dyspnea 8( 9 )3( 3 )0 0 1 3 ( 1 6 ) 4( 5 )0 0
Cough 7( 8 )1( 1 )0 0 1 3 ( 1 6 ) 1( 1 )0 0
Dermatology
Skin 15 (17) 7 (8) 4 (5) 0 15 (19) 11 (14) 2 (2) 1 (1)
Local 1( 1 )0 1( 1 )0 5( 6 )1( 1 )1( 1 )0
Metabolic
Hyperglycaemia 7( 8 )3( 3 )3( 3 )0 5( 6 )3( 4 )0 0
Hypoglycaemia 1( 1 )2( 2 )4( 5 )2( 2 )1( 1 )3( 4 )0 1( 1 )
Considering severe toxicity (grades 3 and 4), fatigue and
fever, leukopenia and granulocytopenia, elevation of liver
enzymes and mood alteration were the most common
side effects reported. The only statistically significant dif-
ference was related to leukopenia, which was more fre-
quent in the DD/DI arm than the HDI arm (24.4% vs.
8.7% respectively, p = 0.0074); yet, this increase was not
associated to a higher risk of infectious disease.
Two patients, one in DD/DI arm and one in HDI arm, suf-
fered from a significant pulmonary toxicity, clinically
characterized by a short history of progressive exertional
dyspnea associated with dry cough, muscular pain and
fever. The patient in DD/DI arm became symptomatic
after the 20th week of intravenous IFNα2b administration
(14 MU/m2), the patient in HDI arm became sympto-
matic during the 52nd  week of subcutaneous IFNα2b
administration (8 MU/m2). On auscultation, bibasilar
coarse crackles were present, chest X-ray revealed patchy
bilateral peripheral infiltrates and reticulonodular opaci-
ties. A computed tomography scan (Fig. 1) confirmed
mild ground-glass opacities in both lungs with bronchialBMC Cancer 2006, 6:44 http://www.biomedcentral.com/1471-2407/6/44
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wall and interstitial thickening. Sputum cultures were neg-
ative for bacteria, fungi, and acid-fast bacilli. An IFN-
induced interstitial pneumonitis was suspected, and both
patients were treated with clorfenamine 16 mg/day, and
acetil cysteine, avoiding the use of corticosteroids. We
decided to continue the treatment in the patient in DD/DI
arm at a lower dose of 8 MU/m2. Despite an improvement
in dyspnea and cough, radiographic infiltrates disap-
peared only after the end of treatment (Fig. 2).
Delivered treatment and dose intensity
Overall, 973 cycles were delivered, 272 in DD/DI arm and
701 in HDI arm. Dose modification was necessary in 200
(73.5%) cycles in DD/DI arm and in 514 (73.3%) cycles
in HDI arm, respectively, and this dose reduction was
higher than 20% in 136 cycles (68%) in DD/DI arm and
in 338 (65.8%) in HDI arm. (Table 3).
As shown in table 4, fifty-four patients (62.8%) received
all cycles of DD/DI regimen and 32 patients (40.0%)
completed the HDI regimen. Toxicity was the cause for
treatment discontinuation in 11 patients (12.8%) in DD/
DI arm and 14 (17.5%) in HDI arm. Patient's refusal,
often observed in association with mood alterations (e.g.
minor depression), and not connected to laboratory
abnormalities, was reported in the 12.8% of patients in
DD/DI arm and 18.7% in HDI arm. Disease progression
was the reason for treatment discontinuation in 29
patients (DD/DI + HDI arm, 17.5%).
The fraction of patients able to tolerate ≥ 80% of the target
scheduled dosage of IFN therapy at four points in time is
listed in table 5. At 28 weeks, 36.4% of patients in the DD/
DI arm and 43.4% of patients in the HDI arm had
received ≥ 80% of the planned dose.
The planned dose intensity was 50 MU/m2/week for the
DD/DI arm and 35.4 MU/m2/week for the HDI arm. The
median actual DI was 36.4 MU/m2/week for patients in
the DD/DI arm and 30.7 MU/m2/week in the HDI arm,
respectively. (Table 6) The reduction of actual DI with
respect to the planned DI was greater in DD/DI arm than
in HDI arm, however the administered DI remained sig-
nificantly higher in DD/DI arm (p = 0. 003), irrespectively
to the dose intensity reduction.
Supportive therapy
Supportive therapy is described separately in the first
cycle, similarly for both arms, and subsequent cycles,
because of the different treatment delivery profile (day-
hospital for DD/DI arm and outpatients for the mainte-
nance phase of HDI arm). As expected, supportive therapy
was similar in the first cycle. During the subsequent cycles
of treatment, anti-emetics were used more frequently in
DD/DI arm (62.0% vs. 30.4%, respectively, Table 7).
Table 3: Treatment compliance
Number of cycles (%)
DD/DI arm HDI arm
N° cycles delivered 272 701
According to protocol 72 (26) 187 (27)
Modified in dose less than 20% 64 (23) 176 (25)
Modified in dose more than 20% 136 (50) 338 (48)
Computed tomography scan during the interferon treatment Figure 1
Computed tomography scan during the interferon 
treatment. Computed tomography scan, performed after 
the 20th week for DD/DI patient (left) and during the 52nd 
week for HDI patient (right), confirmed mild ground-glass 
opacities in both lungs with bronchial wall and interstitial 
thickening. Sputum cultures were negative for bacteria, fungi, 
and acid-fast bacilli.
Computed tomography scan after the end of the interferon  treatment Figure 2
Computed tomography scan after the end of the 
interferon treatment. Computed tomography scan for 
DD/DI patient (left) and HDI patient (right) performed after 
the end of treatment showed the disappearance of radio-
graphic infiltrates.BMC Cancer 2006, 6:44 http://www.biomedcentral.com/1471-2407/6/44
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Discussion and conclusion
The present study was undertaken to investigate whether
the risk/benefit ratio of traditional HDI, as introduced by
the ECOG group, could be improved by increasing the
activity of HDI by administering the drug in a dose-dense/
dose-intense (DD/DI) fashion, while maintaining the
known toxicity profile.
Toxic side effects, uncertainties about its efficacy, its rela-
tive economic burden, and burdensome treatment dura-
tion, have led many physicians to question the risk/
benefit ratio of HDI as adjuvant therapy in melanoma
patients at high risk of recurrence [11]. The evaluation of
the safety profile of the intensified schedule was therefore
one of our main concerns and priorities. Thus, it was also
important to learn whether we would be able to adminis-
ter the intended dose of this intense treatment as planned.
The analysis of toxicity and drug delivery data, on the first
166 patients who entered this study and completed the
treatment, shows that we were able to deliver a signifi-
cantly intensified treatment in the DD/DI arm, without a
significant increase in the overall toxicity when compared
to the standard HDI therapy.
It is noteworthy that the percentage of patients who
received at least 80% of the planned dosage during the
induction phase (65%) and the maintenance phase
(53%) in HDI arm of this study was similar to those
reported in the E1690 and 1684 trials [5,12]. Thus, we
were able not only to increase the weekly dose by 17% in
the experimental arm, but also to deliver the whole dose
intravenously.
Moreover, the overall toxicity observed in the HDI arm of
this study was not different from that previously reported
by Kirkwood et al [5,12,13].
In the experimental arm, only leukopenia significantly
increased (24.4% vs. 8.7%, p = 0.00074) with respect to
the HDI arm: this was associated with an increase in neu-
tropenia (44% vs 28%). Despite this higher incidence of
leukopenia and neutropenia, neutropenic infections were
never recorded and the most often observed infective dis-
eases were primarily skin and cellulite infections localized
in the region of the previous lymphadenectomy. This
occurrence did not seem to be treatment related, since it
was observed in some cases before the start of treatment
and, in other cases, even one or two years after its conclu-
sion. Flu-like symptoms and fatigue intensity, experienced
by nearly all patients, receded almost completely during
the interval-month of DD/DI treatment, although we
observed an increase in its frequency and severity in the
subsequent cycles. This represented the main reason for
an increased dose reduction in the third and fourth cycle
in the experimental arm. On the contrary, the patients in
the HDI arm tend to develop a better tolerance to fatigue
and flu-like symptoms during the course of the treatment
as a consequence of an adaptive reaction to the aforemen-
tioned specific side effects. An increase in the IFN tolera-
bility in the patients treated with repeated cycles of
intravenous high-doses, was observed by Von Wusson P.
et al [14], using an interval as long as three months
Table 5: Proportion of patients who received more than 80% of the target dose
Number of patients (%)
Time from 
randomization
DD/DI arm (N = 86) HDI arm(N = 80)
Induction 56 (65) 52 (65)
3 months 35 (49) 42 (64)
5 months 25 (42) 33 (55)
7 months 20 (36) 23 (43)
Table 4: Number of patients who completed treatment and reasons for discontinuation
Number of patients (%)
DD/DI arm (N = 86) HDI arm(N = 80)
Completed therapy 54 (63) 32 (40)
Reasons for discontinuation
Toxicity 11 (13) 14 (17)
Refusal 11 (13) 15 (19)
Disease Progression 10 (12) 19 (24)BMC Cancer 2006, 6:44 http://www.biomedcentral.com/1471-2407/6/44
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between the cycles. Since, in our study, the interval
between the cycles was one month, the subsequent cycles
started with incomplete resolution of the previous related
effects. Hepatic, gastrointestinal, neurologic, pulmonary,
metabolic, and dermatological toxicities are very similar
in incidence and severity, in both arms and comparable to
those previously reported in the ECOG and Inter-group
trials. Even if the dose intensity we were able to deliver in
the experimental arm was significantly higher (p = 0.003)
than that delivered in HDI arm, the proportion of patients
who discontinued the treatment for toxicity or refusal was
not significantly higher (26 vs. 36 respectively, p = 0.18).
The IFN-induced interstitial pneumonitis we observed in
two cases was first described in 1993 in a patient with
renal cell carcinoma [15]. Other cases have been described
in patients with hepatitis C [16], or chronic myelogenous
leukemia [17], although these are the only melanoma
cases reported to our knowledge. The incidence of this
complication, analyzed in 545 patients affected by
chronic hepatitis C, was less than 1% (4 cases) [18], and
all patients recovered after IFN withdrawal and corticos-
teroid therapy. We tried to avoid the use of steroids in our
patients with the aim of not perturbing the possible
immunologic anti-tumor effects related to IFNα2b: the
complete clinical resolution of the interstitial pneumonia
observed in our two cases, proved that the use of steroids
is not always essential. This severe, even rare, complica-
tion, reported also during the pegylated interferon alpha
2b treatment [19], should be taken into account since, in
our first case, it was firstly mistaken for metastatic lung
lymphangitis.
The main end-point of this study is to investigate whether
the increase of dose intensity, and the related increase in
IFN concentration, obtained by the exclusive intravenous
administration of IFNα2b, could translate into a signifi-
cantly better 5-year overall survival with respect to the
ECOG 1684 schedule. Moreover, an increased benefit
combined with the shortening in the treatment duration
could offset the acknowledged toxicity of high-dose IFNα.
The data derived from this planned analysis on safety and
delivered dose demonstrated that our experimental sched-
ule is feasible and gives us sound ground to continue
patient accrual in order to meet the primary end-point
efficacy.
Since the main toxicities related to the use of high-dose
interferon are quickly recovered after its withdrawal, and
thanks to the shortening of the whole duration of the
treatment by five months (42%), our schedule could have
a great positive impact in the risk/benefit ratio of high
dose interferon.
Table 7: Supportive therapy
Number of patients (%)
Cycle 1 (intravenously) DD/DI arm (N = 86) HDI arm (N = 80)
Paracetamol 79 (92) 71 (89)
Anti-emetics 47 (55) 44 (55)
Anti-diarrhea 3 (3) 2 (2)
Anti-anxiety 20 (23) 15 (19)
V i t a m i n 2 2( 2 6 )1 5( 1 9 )
Subsequent cycles DD/DI arm (N = 71) HDI arm (N = 69)
Paracetamol 64 (90) 55 (80)
Anti-emetics 44 (62) 21 (30)
Anti-diarrhea 6 (8) 2 (3)
Anti-anxiety 19 (27) 16 (23)
V i t a m i n 2 1( 3 0 )1 8( 2 6 )
Table 6: Dose of interferon received and actual dose intensity.
DD/DI arm (N = 86) HDI arm (N = 80)
Mean (SD) Median (Range) Mean (SD) Median (Range)
Target dose (MU/m2)1 6 0 0 1 8 4 0
MU/m2 received 974.6 (455.6) 1034.4 (40 -1620.2) 1052.2 (509.2) 1155.9 (20-1888.9)
Target DI* MU/m2/week 50 35.4
Actual DI MU/m2/week 37.1 (10.8) 36.4 (5–52.1) 34.1 (14.4) 30.7 (5–91.8)
% of target DI 0.74 (0.2) 0.73 (0.1–1.0) 0.96 (0.4) 0.87 (0.1–2.6)
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